New pill takes on tough blood cancers in early human trial

NCT ID NCT04775745

First seen Feb 22, 2026 · Last updated Jun 15, 2026 · Updated 17 times

Summary

This early-stage study tests an experimental oral drug, LP-168, in about 60 people with certain blood cancers (like CLL, lymphoma) that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand how the drug works in the body. Researchers will also look for signs that the drug shrinks tumors or slows the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Duke Univerisity

    RECRUITING

    Durham, North Carolina, 27708, United States

  • Huntsman Cancer Institute, University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • University of Cincinnati

    RECRUITING

    Cincinnati, Ohio, 45221, United States

Conditions

Explore the condition pages connected to this study.